In This Issue

Plus: Opportunity of the Month, and a note from the editor on what's next.

Why AeternuVita Insights — and Why Now?

Scientific discovery is accelerating, but access to useful scientific information remains remarkably uneven. Every week, funding calls open and close. New medicines receive regulatory approval. Clinical trials report results. Researchers publish potentially transformative discoveries. Conferences create opportunities for collaboration. Fellowships capable of changing scientific careers appear across different continents.

The challenge is increasingly not the absence of information. It is finding the right information at the right time — and understanding why it matters.

AeternuVita Insights begins with that challenge. Our vision is to create a trusted meeting point between discovery, medicine and opportunity. We will follow important developments from molecules at the laboratory bench through preclinical development, clinical trials and ultimately patient care. Alongside the science, we will identify funding, fellowships, conferences, training and collaborative opportunities that can help researchers move their ideas and careers forward.

Particular attention will be given to opportunities accessible to researchers in Africa and other low- and middle-income settings, without losing our global perspective. This publication will evolve with its community. But its guiding philosophy will remain unchanged: science should ultimately improve life.

AMR: We Have a Pipeline — But Is It Enough?

Antimicrobial resistance is not simply a microbiology problem. It threatens surgery, cancer chemotherapy, transplantation, neonatal care, and virtually every area of medicine that depends on reliable control of bacterial infection.

WHO's antibacterial pipeline analysis provides an uncomfortable picture: of the antibacterial products in clinical development, only a minority target WHO bacterial priority pathogens, and fewer still satisfy WHO's own criteria for genuine innovation. The preclinical landscape is larger — but the large majority of that early-stage work is concentrated in high-income countries.

The problem therefore extends beyond discovering another antibacterial molecule. The field needs genuinely differentiated mechanisms, activity against priority resistant pathogens, successful translation through clinical development, sustainable commercial models, and equitable access to resulting medicines.

What should researchers watch?

New mechanisms of action — compounds capable of attacking bacterial vulnerabilities not exploited by existing antibiotic classes.
Resistance-breaking combinations — strategies that restore activity to existing drugs or inhibit resistance mechanisms.
Pathogen-specific therapeutics — precision approaches that may reduce unnecessary microbiome disruption.
Non-traditional antibacterials — phages, antibodies, peptides, antivirulence agents, and microbiome-based interventions.
Translation, not activity alone — a compound with an excellent MIC is the beginning of a drug-development story, not its conclusion.

New Medicines Worth Knowing

The US FDA had listed 36 novel drug approvals for 2026 by 28 August. Among the most recent are several scientifically interesting examples.

Also worth watching: in June 2026, the FDA approved tebipenem pivoxil (Utebzi) — described by the agency as the first oral carbapenem therapy for complicated urinary tract infections, an important development from an antimicrobial-drug perspective.

Trials and Therapeutic Programmes to Watch

One purpose of this section will be to follow medicines before they reach pharmacies.

A major recent example comes from lung cancer. A late-stage study of osimertinib plus savolitinib in previously untreated EGFR-mutated advanced non-small-cell lung cancer with MET overexpression reported improved progression-free survival compared with osimertinib alone.

The broader lesson extends beyond this particular combination: combination precision therapy is becoming increasingly important. Tumours evolve. Signalling networks compensate. Resistance emerges. Future oncology will increasingly require researchers to understand not only which molecular target drives a cancer, but also which escape pathways become important when that target is inhibited.

In future issues, Trial Radar will track:

Phase I — Is the intervention sufficiently safe, and what dose should advance?
Phase II — Is there an early signal of therapeutic activity?
Phase III — Does the intervention outperform or add meaningful value to current care?
Regulatory milestone — Has the evidence become strong enough to change treatment?

Opportunities Open Now

Opportunities With Particular Relevance to African Researchers

AREF–MRC Towards Leadership Programme 2026/27

The Africa Research Excellence Fund and UKRI Medical Research Council programme is designed to strengthen the capacity of emerging African researchers to compete for major global-health funding. The programme targets researchers who are citizens of African countries, employed by recognised African universities or research institutions, and at the early stages of leading research teams.

Global Health EDCTP3

The 2026 programme demonstrates the scale of Africa–Europe investment now entering infectious-disease and health-system research. Its competitive calls include programmes addressing TB drug development, lower respiratory tract infections, HIV co-infections and co-morbidities, climate and health, ethics/regulation/pharmacovigilance, and digital innovation and AI in African healthcare. For researchers building African clinical and translational collaborations, EDCTP should remain permanently on the funding radar.

ALC Fellowship Programme — 4th Round (2026–2027)

A research capacity-building initiative supporting PhD, postdoctoral, and early-career researchers working on leishmaniasis (a neglected tropical disease) across Africa. Supports development of independent research leaders in epidemiology, diagnostics, and treatment strategy for this disease area.

September Deadlines & Positions Worth Checking

Where Science Is Meeting Next

Daraxonrasib

When a Historically Difficult Target Becomes Drugable

RAS mutations are among the most important oncogenic alterations in human cancer, but the structural and biochemical properties of RAS proteins historically made direct pharmacological inhibition exceptionally challenging.

That landscape is changing. The August 2026 FDA approval of daraxonrasib for metastatic pancreatic adenocarcinoma provides an excellent case study in an important principle of modern drug discovery:

C₄₄H₅₈N₈O₅S  ·  MW 810.4  ·  CAS 2765081-21-6

A macrocyclic, non-covalent pan-RAS(ON) inhibitor — thiazole core, piperazic-acid-containing macrolactone, and an atropisomeric indole–pyridine biaryl linkage.

Advances in structural biology, medicinal chemistry, molecular pharmacology, and precision oncology can progressively transform difficult biological targets into therapeutic opportunities. That principle extends far beyond cancer.

Your Molecule Is Active. Is It a Drug?

Researchers understandably celebrate when a newly synthesized compound produces impressive biological activity. But the distance between an active compound and an approved medicine is enormous.

And even then the story continues through pharmacovigilance, implementation, access, and real-world evidence.

Resources Worth Bookmarking

Future issues will introduce specialist resources for drug discovery, structural biology, computational chemistry, genomics, funding intelligence, and scientific writing.

Introducing AeternuVita

AeternuVita is being built around a simple conviction: science should not end with discovery — it should reach humanity.

Our scientific interests sit at the intersection of chemistry, biology, and medicine, with a long-term focus on therapeutic discovery and translation for some of humanity's most difficult health challenges.

But AeternuVita is also about people. We believe scientific impact requires researchers to have access not only to laboratories, but also to knowledge, mentorship, collaboration, and opportunity. AeternuVita Insights is one step toward building that ecosystem — starting from an active research programme today, growing deliberately from there.